GRDN Relative Valuation
GRDN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, GRDN is overvalued; if below, it's undervalued.
Historical Valuation
Guardian Pharmacy Services Inc (GRDN) is now in the Overvalued zone, suggesting that its current forward PE ratio of 28.26 is considered Overvalued compared with the five-year average of 24.67. The fair price of Guardian Pharmacy Services Inc (GRDN) is between 22.87 to 27.48 according to relative valuation methord. Compared to the current price of 29.32 USD , Guardian Pharmacy Services Inc is Overvalued By 6.71%.
Relative Value
Fair Zone
22.87-27.48
Current Price：29.32
6.71%
Overvalued
28.26
PE
1Y
3Y
5Y
Trailing
Forward
17.09
EV/EBITDA
Guardian Pharmacy Services Inc. (GRDN) has a current EV/EBITDA of 17.09. The 5-year average EV/EBITDA is 14.99. The thresholds are as follows: Strongly Undervalued below 11.99, Undervalued between 11.99 and 13.49, Fairly Valued between 16.49 and 13.49, Overvalued between 16.49 and 17.98, and Strongly Overvalued above 17.98. The current Forward EV/EBITDA of 17.09 falls within the Overvalued range.
23.27
EV/EBIT
Guardian Pharmacy Services Inc. (GRDN) has a current EV/EBIT of 23.27. The 5-year average EV/EBIT is 21.00. The thresholds are as follows: Strongly Undervalued below 16.52, Undervalued between 16.52 and 18.76, Fairly Valued between 23.24 and 18.76, Overvalued between 23.24 and 25.48, and Strongly Overvalued above 25.48. The current Forward EV/EBIT of 23.27 falls within the Overvalued range.
1.27
PS
Guardian Pharmacy Services Inc. (GRDN) has a current PS of 1.27. The 5-year average PS is 1.06. The thresholds are as follows: Strongly Undervalued below 0.82, Undervalued between 0.82 and 0.94, Fairly Valued between 1.19 and 0.94, Overvalued between 1.19 and 1.31, and Strongly Overvalued above 1.31. The current Forward PS of 1.27 falls within the Overvalued range.
19.60
P/OCF
Guardian Pharmacy Services Inc. (GRDN) has a current P/OCF of 19.60. The 5-year average P/OCF is 12.12. The thresholds are as follows: Strongly Undervalued below -6.90, Undervalued between -6.90 and 2.61, Fairly Valued between 21.63 and 2.61, Overvalued between 21.63 and 31.14, and Strongly Overvalued above 31.14. The current Forward P/OCF of 19.60 falls within the Historic Trend Line -Fairly Valued range.
29.50
P/FCF
Guardian Pharmacy Services Inc. (GRDN) has a current P/FCF of 29.50. The 5-year average P/FCF is 18.04. The thresholds are as follows: Strongly Undervalued below -8.61, Undervalued between -8.61 and 4.72, Fairly Valued between 31.36 and 4.72, Overvalued between 31.36 and 44.68, and Strongly Overvalued above 44.68. The current Forward P/FCF of 29.50 falls within the Historic Trend Line -Fairly Valued range.
Guardian Pharmacy Services Inc (GRDN) has a current Price-to-Book (P/B) ratio of 10.10. Compared to its 3-year average P/B ratio of 8.80 , the current P/B ratio is approximately 14.75% higher. Relative to its 5-year average P/B ratio of 8.80, the current P/B ratio is about 14.75% higher. Guardian Pharmacy Services Inc (GRDN) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of 3.18%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of 3.18% , the current FCF yield is about -100.00% lower.
10.10
P/B
Median3y
8.80
Median5y
8.80
3.68
FCF Yield
Median3y
3.18
Median5y
3.18
Competitors Valuation Multiple
The average P/S ratio for GRDN's competitors is , providing a benchmark for relative valuation. Guardian Pharmacy Services Inc Corp (GRDN) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 20.05%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of GRDN increased by 44.72% over the past 1 year. The primary factor behind the change was an increase in P/E Change from 45.29 to 105.18.
The secondary factor is the Revenue Growth, contributed 20.05%to the performance.
Overall, the performance of GRDN in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
FAQ
Is Guardian Pharmacy Services Inc (GRDN) currently overvalued or undervalued?
What is Guardian Pharmacy Services Inc (GRDN) fair value?
How does GRDN's valuation metrics compare to the industry average?
What is the current P/B ratio for Guardian Pharmacy Services Inc (GRDN) as of Dec 05 2025?
What is the current FCF Yield for Guardian Pharmacy Services Inc (GRDN) as of Dec 05 2025?
What is the current Forward P/E ratio for Guardian Pharmacy Services Inc (GRDN) as of Dec 05 2025?